特別セッション 2　核医学の礎である放射化学の新展開

[1A02] Development of pre-targeting system using low immunogenic streptavidin mutants and 211-At-labeled bis-iminobiotin

*Toshifumi Tatsumi¹, Kenzo Yamatsugu¹, Akira Sugiyama², Songji Zhao³, Miho Aoki³, Ken-ichi Nishijima³, Naoyuki Ukon³, Saki Shimoyama³, Tan Chengbo³, Taiki Joho³, Noboru Oriuchi³, Kazuhiro Takahashi³, Yohei Shimizu¹, Kazuki Takahashi¹, Sho Aki⁴, Tatsuhiko Kodama⁴, Kohshin Washiyama³, Motomu Kanai¹ (1. Grad. Sch. Pharm. Sci., The University of Tokyo., 2. Isotope Science Center, The University of Tokyo, 3. Advanced Clinical Research Center, Fukushima Medical University,, 4. Research Center for Advanced Science and Technology, The University of Tokyo)